This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

WebMD/Medscape Special Report: Marijuana On Main Street While Doctors Favor Legalization More Than Consumers, Opinions Differ By Specialty

NEW YORK, April 2, 2014 /PRNewswire/ -- WebMD Health Corp. (Nasdaq: WBMD), the leading source of health information, today released Marijuana on Main Street , a special report that provides an in-depth look at the debate over medical marijuana.  As numerous states consider bills to legalize medical marijuana, WebMD surveyed nearly 3,000 consumers and Medscape surveyed more than 1,500 doctors about their attitudes regarding legalization, marijuana as a potential treatment option, and the perceived risks and benefits of its use to help shed light on this evolving issue.  

To view the multimedia assets associated with this release, please click:  http://www.multivu.com/mnr/7040258-webmd-medscape-medical-marijuana-report

The Marijuana on Main Street special report includes full survey findings, analysis, expert commentary and patient stories. 

"Despite more than 20 years of anecdotal evidence about the medicinal effects of marijuana, doctors and consumers remain in search of answers," says Dr. Michael Smith, Chief Medical Editor, WebMD.  "The findings of our consumer-physician survey indicate the medical community's support for the use of marijuana as a treatment option, particularly among clinical specialties that have pioneered research.  Yet these survey data suggest additional studies will inform decision-makers' confidence in where medical marijuana can help and where it might not."

PHYSICIAN OPINIONS ON LEGALIZATION

Amid ongoing debate of whether medical marijuana should be legalized nationally, the Medscape survey finds that overall, 56% of respondents are in favor of national legalization.  Peer-review data on marijuana's health benefits remain limited.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,764.72 +134.45 0.76%
S&P 500 2,105.22 +11.97 0.57%
NASDAQ 5,102.1330 +12.9270 0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs